A Randomized, Open-Label, Active-Controlled, Phase II Study of Intravenous Anetumab Ravtansine (BAY 94-9343) or Vinorelbine in Patients with Advanced or Metastatic Malignant Pleural Mesothelioma Overexpressing Mesothelin and Progressing on First Line Platinum/Pemetrexed-Based Chemotherapy

The primary objective of this study is to:
Test the superiority of anetumab ravtansine monotherapy over vinorelbine in progression-free survival (PFS)
The secondary objectives of this study are to:
Test overall survival (OS)
Evaluate pulmonary function
Evaluate patient-reported outcomes (PROs) ¿ symptom burden and health-related quality of life (QoL)
Evaluate other indicators of treatment efficacy (indicators of tumor response)
Evaluate safety

Study Number: 

PH 276715

Principal Investigator: 
ClinicalTrials.Gov ID: 

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.